Vaccination with TAT-antigen fusion protein induces protective, CD8 T cell-mediated immunity against leishmania major

Journal of Investigative Dermatology

Volumn 130, Issue 11, 2010, Pages 2602-2610

  Kronenberg, Katharina ^a   Brosch, Sven ^a   Butsch, Florian ^a   Tada, Yayoi ^b,c   Shibagaki, Naotaka ^b,d   Udey, Mark C ^b   Von Stebut, Esther ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 4; LEISHMANIA HOMOLOG OF RECEPTORS FOR ACTIVATED C KINASE; LEISHMANIA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN LEISHMANIA HOMOLOG OF RECEPTORS FOR ACTIVATED C KINASE FUSION PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL EVALUATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; IMMUNOGENICITY; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VACCINE PRODUCTION;

EID: 77957934708     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.171     Document Type: Article

References (46)

1. Ahuja SS, Reddick RL, Sato N et al. (1999) Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol 163:3890-7
2. Amigorena S (2002) Fcg receptors and cross-presentation in dendritic cells. J Exp Med 195:F1-3
3. Belkaid Y, Hoffmann KF, Mendez S et al. (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194:1497-506
4. Belkaid Y, Mendez S, Lira R et al. (2000) A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 165:969-77
5. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168:3992-4000
6. Berberich C, Ram?́rez-Pineda JR, Hambrecht C et al. (2003) Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC derived IL-12 and can be induced by molecularly defined antigens. J Immunol 170:3171-9
7. + T cells by Leishmania major-infected dendritic cells. Infect Immun 73:6620-8
8. Dondji B, Deak E, Goldsmith-Pestana K et al. (2008) Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol 38:706-19
9. + T cells do not mediate a protective immune response. Immunobiology 195:243-60
10. Flohe SB, Bauer C, Flohe S et al. (1998) Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major. Eur J Immunol 28:3800-11
11. Geiger B, Wenzel J, Hantschke M et al. (2010) Resolving lesions in human cutaneous leishmaniasis predominantly harbour chemokine receptor CXCR3-positive T helper 1/T cytotoxic type 1 cells. Br J Dermatol 162:870-4
12. Ghosh M, Pal C, Ray M et al. (2003) Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. J Immunol 170:5625-9
13. Gurunathan S, Sacks DL, Brown DR et al. (1997) Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186:1137-47
14. + T cells. J Immunol 165:915-24
15. Heinzel FP, Sadick MD, Holaday BJ et al. (1989) Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 169:59-72
16. Iezzi G, Fröhlich A, Ernst B et al. (2006) Lymph node resident rather than skin-derived dendritic cells initiate specific T cell responses after Leishmania major infection. J Immunol 177:1250-6
17. Inaba K, Inaba M, Romani N et al. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693-702
18. Jensen KDC, Sercarz EE, Gabaglia CR (2009) Altered peptide ligands can modify the Th2 T cell response to the immunodominant 161-175 peptide of LACK (Leishmania homolog for the receptor of activated C kinase). Mol Immunol 46:366-74
19. Kharazmi A, Kemp K, Ismail A et al. (1999) T-cell response in human leishmaniasis. Immunol Lett 65:105-8
20. + dendritic cells is sufficient for control of Leishmania major. J Exp Med 199:725-30
21. Mitsui H, Inozume T, Kitamura R et al. (2006) Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. J Invest Dermatol 126:1804-12
22. Moll H, Flohe S, Rollinghoff M (1995) Dendritic cells in Leishmania major-immune mice harbor persistent parasites and mediate an antigen-specific T cell immune response. Eur J Immunol 25:693-9
23. Mougneau E, Altare F, Wakil AE et al. (1995) Expression cloning of a protective Leishmania antigen. Science 268:563-6
24. + T cells. Int Immunol 3:587-97
25. Murray HW, Berman JD, Davies CR et al. (2005) Advances in leishmaniasis. Lancet 366:1561-77
26. Ramirez-Pineda JR, Frohlich A, Berberich C et al. (2004) Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol 172:6281-9
27. Reiner SL, Locksley RM (1995) The regulation of immunity to Leishmania major. Annu Rev Immunol 13:151-77
28. Ritter U, Osterloh A (2007) A new view on cutaneous dendritic cell subsets in experimental leishmaniasis. Med Microbiol Immunol 196:51-9
29. Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2:845-58
30. Saha S, Mondal S, Banerjee A et al. (2006) Immune responses in kala-azar. Indian J Med Res 123:245-66
31. Sato N, Ahuja SK, Quinones M et al. (2000) CC chemokine receptor (CCR)2 is required for Langerhans cell migration and localization of T helper cell type 1 (Th1)-inducing dendritic cells. Absence of CCR2 shifts the Leishmania major-resistant phenotype to a susceptible state dominated by Th2 cytokines, B cell outgrowth, and sustained neutrophilic inflammation. J Exp Med 192:205-18
32. Shah JA, Darrah PA, Ambrozak DR et al. (2003) Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J Exp Med 198:281-91
33. Shibagaki N, Udey MC (2002) Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 168:2393-401
34. Shibagaki N, Udey MC (2003) Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol 33:850-60
35. Stacey KJ, Blackwell JM (1999) Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 67:3719-26
36. + T cells. J Exp Med 199:1559-66
37. Van Weyenbergh J, Santana G, D'Oliveira A Jr et al. (2004) Zinc/copper imbalance reflects immune dysfunction in human leishmaniasis: an ex vivo and in vitro study. BMC Infect Dis 17:50
38. Vanloubbeeck Y, Jones DE (2004) The immunology of Leishmania infection and the implications for vaccine development. Ann NY Acad Sci 1026:267-72
39. von Stebut E (2007) Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Dermatol 17:115-22
40. von Stebut E, Belkaid Y, Jakob T et al. (1998) Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med 188:1547-52
41. von Stebut E, Belkaid Y, Nguyen BV et al. (2000) Leishmania major-infected murine Langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous leishmaniasis. Eur J Immunol 30:3498-506
42. Wadia JS, Dowdy SF (2005) Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 57:579-96
43. Walker PS, Scharton-Kersten T, Krieg AM et al. (1999) Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12-and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci USA 96:6970-5
44. Woelbing F, Lopez Kostka S, Moelle K et al. (2006) Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J Exp Med 203:177-88
45. Zaph C, Uzonna J, Beverley SM et al. (2004) Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med 10:1104-10
46. Zimmermann S, Egeter O, Hausmann S et al. (1998) CpG oligodeoxynucleo- tides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 160:3627-30